Journal article

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy

Shuo Ma, John F Seymour, Danielle M Brander, Thomas J Kipps, Michael Y Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W Roberts

BLOOD | AMER SOC HEMATOLOGY | Published : 2021

Abstract

We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (200-600 mg) and rituximab over 6 months and then received venetoclax monotherapy. Patients achieving complete response (CR), CR with incomplete marrow recovery (CRi), or undetectable minimal residual disease (uMRD) assessed by flow cytometry (2 years off venetoclax (range, 2.1-6.4). Four patients were retreated with VenR, with partial responses observed in the 3 evaluable to date. VenR induced deep responses that were highly durable with either co..

View full abstract

Grants

Awarded by Genentech


Funding Acknowledgements

AbbVie and the authors thank the patients, their families and caregivers, as well as the study investigators, research, and supporting staff. No honoraria or payments were made for authorship. Venetoclax (ABT199/GDC-0199) is being developed in a collaboration between AbbVie and Genentech.AbbVie and Genentech funded this study (NCT01682616) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. Medical writing support was provided by Mary L. Smith, CMPP (Aptitude Health, Atlanta, GA) and was funded by AbbVie.